Evidence map›Paper›PMID 35046666›Full record

ArticleOncoTargets and therapy2022

Prognostic Implications of Six Altered Genes in Asian Non-Surgical Esophageal Carcinoma Patients Treated with Chemoradiotherapy.

Alei Feng, Ning Yang, Ruoying Yu, Jingwen Liu, Jiaohui Pang, Xue Wu, Yang Shao, Zhe Yang, Honghai Dai

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Alei FengTumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, People's Republic of China.
Ning YangTumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, People's Republic of China.
Ruoying YuNanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People's Republic of China.ORCID 0000-0003-1560-239X
Jingwen LiuNanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People's Republic of China.ORCID 0000-0001-6472-5025
Jiaohui PangNanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People's Republic of China.
Xue WuNanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People's Republic of China.
Yang ShaoNanjing Geneseeq Technology Inc., Nanjing, Jiangsu, People's Republic of China.
Zhe YangTumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, People's Republic of China.
Honghai DaiTumor Research and Therapy Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, People's Republic of China.
Shandong Provincial Hospital · CNNanjing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEsophageal cancer (EC), especially esophageal squamous cell carcinoma, remained as one of the most aggressive tumors in China with a five-year survival rate of around 40%. Molecular characteristics through next-generation sequencing are becoming an emerging method in identifying prognostic biomarkers for better treatment management for EC patients.

methodsTargeted next-generation sequencing using a 422-gene pan-cancer panel was performed with tumor tissue samples from a total of 69 Asian non-surgical esophageal carcinoma patients (AEC) treated with chemoradiotherapy. A TCGA cohort of 143 EC patients and another Asian ESCC cohort of 47 patients were employed for validation.

resultsIn the AEC cohort, alterations in

conclusionSix gene alterations were found to be potential unfavorable prognostic markers that might provide guidance in the treatment management for EC patients.

Indexed as

BAP1BRIP1chemoradiotherapyesophageal cancerMYCoverall survivalRB1WRNYAP1

Identifiers

PMID35046666
PMCPMC8763582
OpenAlexW4205369429

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.